Jacob McCright
![Jacob McCright Jacob McCright](https://cytokine-based-drugdevelopment.com/wp-content/uploads/sites/349/2024/04/Jacob-McCright-150x150.jpg)
Company: DEKA Biosciences
Job title: Scientist II
Seminars:
Combining DK210 (CD20) With BiTE’s to Block Cytokine Release Syndrome 12:00 pm
Combining anti-CD19 BiTE’s in vitro dramatically enhances T cell cytolysis of tumors when combined with as low as 0.1 ng/mL BiTE concentrations Blunting BiTE mediated cytokine release syndrome Enhancing tumor responses while suppressing CRS, suggesting DK210 (tumor target) may represent a potent combination partner with BiTE platforms Read more
day: Conference Day Two